Nurse Practitioner in Brisbane, CA Accepting Medicare
3 Nurse Practitioner nurses found. Showing 1 - 3
 Daniel Gordon, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 8000 Marina Blvd Ste 600, Brisbane, CA 94005 Phone: 415-514-3577 |
 Thao Nguyen, FNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 453 San Francisco Ave, Brisbane, CA 94005 Phone: 925-497-0188 |
Helen Horvath, Nurse Practitioner - Adult Health Medicare: Medicare Enrolled Practice Location: 8000 Marina Blvd Ste 600, Brisbane, CA 94005 Phone: 415-514-3577 |
News Archive
New compound may lead to development of potential therapeutics for neuropathic pain
A new compound discovered by a team of UC Davis investigators has potent actions against production of a chemical that which is implicated in the development of chronic pain following a peripheral nerve injury in the spinal cord.
Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials
Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).
Changes to state law reduce new opioid prescriptions by 22% in Penn Medicine's New Jersey practices
The total amount of opioids dispensed per new opioid prescription decreased by 22 percent in Penn Medicine outpatient practices in New Jersey after the state passed a law limiting prescriptions to a five-day supply for new opioid prescriptions.
Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference
Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).
› Verified 5 days ago